Werewolf’s INDUKINE molecules have shown promising safety and efficacy results in ongoing oncology clinical trials. Their validated approach entails the identification of novel protease ...
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) today and set a price target of $12.00. Reni Benjamin’s rating is based on Werewolf ...